OraSure pushes HIV test
This article was originally published in The Tan Sheet
OraSure Technologies continues to seek FDA approval of its OraQuick HIV OTC over-the-counter test based on feedback from a closed-door FDA advisory panel session, the firm says Nov. 18. During a Nov. 17 meeting of FDA's Blood Products Advisory Committee to discuss over-the-counter, home-use HIV test kits, the panel met privately with OraSure to review the results of ongoing clinical studies for its OTC test, and discuss what additional clinical data FDA needs for approval. The firm already markets the OraQuick Advance rapid HIV-12 antibody test, among others
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.